Nuclear theranostics, combined with hybrid imaging (SPECT/CT, PET/CT, PET/MR), are playing a major role in precision medicine, significantly improving disease management—particularly in oncology. Delivered by international leaders in nuclear radiology, this comprehensive symposium on Thursday, August 11, 2022 will detail current and future roles for theranostics in imaging, particularly for patients suffering from neuroendocrine and prostate cancers.
The practice of a fully integrated diagnostic and therapeutic medical imaging specialty requires in-depth knowledge of many different fields of medicine and complex imaging equipment, alongside understanding of patient management and health care system economics. Therefore, “Is Your Practice Ready for the Impact of Theranostics?” will provide both clinical knowledge and financial tips for setting up a theranostics practice.
| SESSION SCHEDULE | ||
| Time | Session Topic | Faculty |
| 12:00 — 12:30 | Jean-Luc Urbain, MD, PhD | |
| 12:30 — 1:00 | Andrew Scott | |
| 1:00 — 1:30 | Homer Macapinlac, MD | |
| 1:30 — 2:00 | Heather A. Jacene, MD | |
| 2:00 — 2:30 | Question and Answer Session | |
| 2:30 — 2:45 | Break | |
| 2:45 — 3:15 | Gholam Berenji, MD | |
| 3:15 — 3:45 | Pat Zanzonico, PhD | |
| 3:45 — 4:15 | Gang Niu, MD, PHD | |
| 4:15 — 4:45 | Daniel Lee, MD | |
| 4:45 — 5:15 | Reginald F. Munden, MD, DMD, MBA | |
